Work

Generation and maintenance of kidney and kidney cancer organoids from patient-derived material for drug development and precision oncology

Year: 2024

Type: article

Abstract: Despite significant advancements in targeted- and immunotherapies, millions of patients with cancer still succumb to the disease each year. In renal cell carcinoma, up to 25% of metastatic patients do not respond to first-line therapies. This reality underscores the urgent need for innovative or repurposed therapies to effectively treat these patients. Patient-derived organoids represent a promising model for evaluating treatment efficacy and toxicity, offering a potential breakthrough in personalized medicine. However, utilizing organoid models for drug screening presents several challenges. Our protocol aims to address these obstacles by outlining a practical approach to successfully isolate and cultivate patient-derived renal cell carcinoma and kidney organoids for treatment screening purposes.

Source: Molecular Therapy — Methods & Clinical Development

DOI: 10.1016/j.omtm.2024.101368

Authors: Jakub Gubala, Valentin Mieville, Daniel Benamran, Jean-Christophe Tille, Massimo Valerio, Patrycja Nowak-Sliwinska

Institutions: University of Geneva, University Hospital of Geneva

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,900